First Patient Dosed in Phase 1 Trial of BT-001 for Rectal Cancer

The first patient has been dosed in a Phase 1 clinical trial evaluating BT-001, a therapy developed by Transgene and BioInvent, for patients with rectal cancer. This marks the initiation of early-stage testing to assess the treatment's safety and potential efficacy.

Originally published by gnews